Lesogaberan: GABAB receptor agonist treatment of gastroesophageal reflux disease

Drugs of the Future

Volumn 35, Issue 12, 2010, Pages 987-992

  Lacy, Brian E ^a   Chehade, Robert ^a   Crowell, Michael D ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACLOFEN; CLOPIDOGREL; ESOMEPRAZOLE; LESOGABERAN; MONOAMINE OXIDASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BINDING AFFINITY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; ESTERIFICATION; FATIGUE; FLUSHING; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; HYDROGENATION; HYPOTENSION; LOW DRUG DOSE; LOWER ESOPHAGUS SPHINCTER PRESSURE; MAXIMUM PLASMA CONCENTRATION; MUSCLE HYPOTONIA; NAUSEA; NONHUMAN; PARESTHESIA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DEPRIVATION; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT LOWER ESOPHAGEAL RELAXATION; TREATMENT RESPONSE; URINE VOLUME;

EID: 79956195307     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.012.1540661     Document Type: Review

References (30)

1. Alstermark, C., Amin, K., Dinn, S.R. et al. Synthesis and pharmacological evaluation of novel γ-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors. J Med Chem 2008, 51(14): 4315-20.
2. Amin, K., Elebring, T., Guzzo, P., Olsson, T., Swanson, M., Von Unge, S. (AstraZeneca AB). (Aminopropyl)methylphosphinic acids. CA 2393510, EP 1239843, US 6596711, WO 2001041743.
3. Elebring, T., Guzzo, P., Holmén, A., Olsson, T., Swanson, M., Von Unge, S. (AstraZeneca AB). New aminopropylphosphinic acids. EP 1240172, EP 1484333, JP 2003516407, JP 2006306885, US 2003220303, US 6841698, US 2005137414, US 2006172979, US 2007021393, US 7319095, US 7807658, WO 2001042252.
4. Locke, G.R., Talley, N.J., Fett, S.L. et al. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 1997, 112(5): 1448-56.
5. Isolauri, J., Laippala, P. Prevalence of symptoms suggestive of gastrooesophageal reflux disease in an adult population. Ann Med 1995, 27(4): 67-70.
6. Chiocca, J.C., Olmos, J.A., Salis, G.B. et al. Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: A nationwide population-based study. Aliment Pharmacol Ther 2005, 22(4): 331-42.
7. Moraes-Filho, J.P., Chinzon, D., Eisiq, J.N. et al. Prevalence of heartburn and gastroesophageal reflux disease in the urban Brazilian population. Arq Gastroenterol 2005, 42(2): 122-7.
8. Cho, Y.S., Choi, M.G., Jeong, J.J. et al. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Asan-si, Korea. Am J Gastroenterol 2005, 100(4): 747-53.
9. Guozong, P., Guoming, X., Meiyun, K. et al. Epidemiological study of symptomatic gastroesophageal reflux disease in China: Beijing and Shanghai. Chin J Dig Dis 2000, 1: 2-8.
10. Spechler, S.J., Lee, E., Ahnen, D. et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial. JAMA 2001, 285(18): 2331-8.
11. Chiba, N., De Gara, C.J., Wilkinson, J.M., Hunt, R.H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997, 112(6): 1798-810.
12. Mittal, R.K., Holloway, R.H., Penagini, R., Blackshaw, L.A., Dent, J. Transient lower esophageal sphincter relaxation. Gastroenterology 1995, 109(2): 601-10.
13. Lehman, A., Antonsson, M., Bremner-Danielsen, M., Flärdh, M., Hansson-Brändén, L., Kärrberg, L. Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999, 117(5): 1147-54.
14. Lidums, I., Lehmann, A., Checklin, H., Dent, J., Holloway, R.H. Control of transient lower esophageal sphincter relaxations and reflux by the GABA-B agonist baclofen in normal subjects. Gastroenterology 2000, 118(1): 7-13.
15. van Herwaarden, M.A., Samsom, M., Rydholm, H., Smout, A.J. The effect of baclofen on gastro-oesophageal reflux, lower esophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002, 16(9): 1655-62.
16. Zhang, Q., Lehmann, A., Rigda, R., Dent, J., Holloway, R.H. Control of transient lower esophageal sphincter relaxations and reflux by the GABA-B agonist baclofen in patients with gastroesophageal reflux disease. Gut 2002, 50(1): 19-24.
17. Andrews, P.L., Bingham, S., Wood, K.L. Modulation of the vagal drive to the intramural cholinergic and non-cholinergic neurons in the ferret stomach by baclofen. J Physiol 1987, 388: 25-39.
18. Page, A.J., Blackshaw, L.A. GABA-B receptors inhibit mechanosensitivity of primary afferent endings. J Neurosci 1999, 19(19): 8597-602.
19. Smid, S.D., Young, R.L., Cooper, N.J., Blackshaw, L.A. GABA-B expressed on vagal afferent neurons inhibits gastric mechanosensitivity in ferret proximal stomach. Gastro Liver Physiol 2001, 281: G1494-501.
20. Lee, K.J., Vos, R., Janssens, J., Tack, J. Differential effects of baclofen on lower oesophageal sphincter pressure and proximal gastric motility in humans. Aliment Pharmacol Ther 2003, 18(2): 199-207.
21. Lehmann, A., Blackshaw, L.A., Elebring, T. et al. The new reflux inhibitor AZD3355 has a low propensity for inducing central side effects due to its affinity for the GABA carrier. Gastroenterology [Dig Dis Week (May 17-22, San Diego) 2008] 2008, 134(4, Suppl. 1): Abst 1789.
22. Lehmann, A., Braenden, L., Carlsson, A. et al. AZD3355, a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxations in the dog. Gastroenterology [Dig Dis Week (May 17-22, San Diego) 2008] 2008, 134(4, Suppl. 1): Abst 376.
23. Lehmann, A., Holmberg, A., Bhatt, U. et al. Effects of (2R)-(3-amino-2- fluoropropyl) sulphinic acid (AFPSiA) on transient lower oesophageal sphincter relaxation in dogs and mechanism of hypothermic effects in mice. Br J Pharmacol 2005, 146(1): 89-97.
24. Lehmann, A., Antonsson, M., Holmberg, A. et al. (R)-(3-Amino-2- fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. J Pharmacol Exp Ther 2009, 331(2): 504-12.
25. Brändén, L., Frederiksson, A., Harring, E., Jensen, J., Lehmann, A. The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pH-metry in dogs. Eur J Pharmacol 2010, 634(1-3): 138-41.
26. Boeckxstaens, G.E., Rydholm, H., Lei, A., Adler, J., Ruth, M. Effect of lesogaberan, a novel GABA-B receptor agonist, on transient lower esophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 2010, 31(11): 1208-17.
27. Niazi, M., Silberg, D.G., Adler, J., Denison, H. Evaluation of pharmacokinetic interaction between esomeprazole and AZD3355, a novel reflux inhibitor, in healthy volunteers. Gastroenterology [Dig Dis Week (May 30- June 4, Chicago) 2009] 2009, 136(5, Suppl. 1): Abst M1872.
28. Fransson, B., Silberg, D.G., Niazi, M., Adler, J., Ruth, M. Effect of food on the bioavailability of AZD3355, a novel reflux inhibitor, in healthy subjects. Gastroenterology [Dig Dis Week (May 30-June 4, Chicago) 2009] 2009, 135(5, Suppl. 1): Abst M1911.
29. Boeckxstaens, G.E., Beaumont, H., Mertens, V. et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010, 139(2): 409-17.
30. Boeckxstaens, G.E., Beaumont, H., Hatlebakk, J.G., Silberg, D.G., Adler, J., Denison, H. Efficacy and tolerability of the novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy. Gastroenterology [Dig Dis Week (May 30- June 4, Chicago) 2009] 2009, 136(5, Suppl. 1): Abst M1875.